Paediatric drug optimization for respiratory syncytial virus: meeting report, April 2025

Overview

This PADO-RSV report outlines tools for the prevention and treatment of respiratory syncytial virus (RSV) in children, focusing on long-acting monoclonal antibodies and antiviral agents. Developed in the context of an evolving landscape this exercise aims to align efforts across the global health ecosystem. The outcome is a PADO priority list (3–5 year horizon) and a watch list (5–10 year horizon), supporting alignment across funders, product developers, regulators, and procurement partners to accelerate access to child-friendly RSV interventions, particularly in low- and middle-income countries.